Rhythm Biosciences Limited
ASX: RHY.AX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- David Atkins
- Employees
- 23
- Headquarters
- Parkville, Australia
- IPO year
- 2017
- Market cap
- A$49.5M
- Website
- https://www.rhythmbio.com
Loading RHY…
Loading profile data…Frequently asked questions about RHY
What does Rhythm Biosciences Limited (RHY.AX) do?
Rhythm Biosciences Limited, a transformative predictive cancer diagnostics technology company in Australia and internationally. The company engages in developing and commercializing medical diagnostics technology. It develops ColoSTAT, a blood test for the early detection of colorectal cancer. The company was incorporated in 2017 and is headquar...
Where does RHY.AX trade?
Rhythm Biosciences Limited (RHY.AX) trades on the Australian Securities Exchange.
What sector is RHY.AX in?
Rhythm Biosciences Limited (RHY.AX) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of Rhythm Biosciences Limited?
David Atkins is the chief executive officer of Rhythm Biosciences Limited (RHY.AX).
Where is Rhythm Biosciences Limited headquartered?
Rhythm Biosciences Limited is headquartered in Australia.
Does RHY.AX pay a dividend?
Rhythm Biosciences Limited (RHY.AX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RHY.AX go public?
Rhythm Biosciences Limited (RHY.AX) completed its initial public offering in 2017.